CA-THERMO-FISHER
11.7.2022 08:02:09 CEST | Business Wire | Press release
Thermo Fisher Scientific, the world leader in serving science, today announced the launch of the Applied Biosystems TaqPath Respiratory Viral Select Panel; a CE-IVD-marked molecular assay panel for detection of five common viruses, including those that cause the common cold, bronchiolitis, croup, influenza-like illnesses, and pneumonia.
The molecular assay panel provides results in approximately three hours, testing for Adenovirus, Human Metapneumovirus, Rhinovirus/Enterovirus, and Parainfluenza virus, using highly accurate PCR technology. RNase P and positive controls are included to offer sample-to-result reliability. The solution is scalable, which allows laboratories to run from one to 94 samples simultaneously depending on the needs of the population they’re servicing and can help to identify co-infections.
“As the world continues to grapple with living alongside COVID-19, it is important to know that there are a myriad of other respiratory viruses that can also cause serious illness,” said Dr. Manoj Gandhi, senior medical director of Genetic Testing Solutions at Thermo Fisher Scientific. “Offering information on these other common respiratory viruses in a single test empowers labs to detect them quickly and efficiently so that the right treatment approach can be selected, which can help save patient’s lives.”
The ongoing pandemic has stressed the importance of making effective diagnostics accessible, and by using existing PCR infrastructure, implemented to manage COVID-19, labs can expand disease state testing without increasing costs. This new panel uses the same workflow as the TaqPath COVID-19, Flu A/B, RSV combo kit when using the Applied Biosystems QuantStudio 5 PCR system. Allowing laboratories to test for eight common respiratory viruses with one patient sample. Adding the panel can help enable labs to add to their molecular testing menu for viral respiratory infections with ease.
For more information on the TaqPath Respiratory Viral Select Panel, please visit https://www.thermofisher.com/taqpathrespviralselect
The TaqPath Respiratory Viral Select Panel is for For In Vitro Diagnostic Use and is only available in select EMEA countries.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of approximately $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD.
For more information, please visit www.thermofisher.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20220710005063/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting styrker sine tilbud inden for digital transformation og cybersikkerhed med HeadMind Partners15.6.2026 15:47:00 CEST | Pressemeddelelse
Andersen Consulting styrker sin platform gennem en samarbejdsaftale med HeadMind Partners, et førende europæisk konsulenthus med speciale i cybersikkerhed, digital transformation og ai. Med sin unikke kombination af 25 års erhvervserfaring og ekspertise inden for teknologi og data hjælper HeadMind Partners sine klienter – store virksomheder fra både den private og offentlige sektor – med at styrke deres digitale modstandskraft og cybersikkerhed, forbedre deres operationelle effektivitet og opbygge robuste og uafhængige ai-løsninger. Virksomheden har hovedsæde i Paris og opererer i dag i Frankrig og Belgien, hvor den trækker på multidisciplinære teams bestående af 500 cybersikkerhedseksperter, 70 ai-ingeniører og 400 specialister i digital transformation for at levere værdiskabende og friktionsfrie løsninger inden for cybersikkerhed, ai og digital transformation. HeadMind Partners betjener en mangfoldig og velanset kundeportefølje på tværs af industri-, energi- og luksusvaresektoren sam
Energy Dome and SRP to Add Long-Duration Energy Storage Project to the Grid, Expand Google Collaboration15.6.2026 15:30:00 CEST | Press release
The pilot will be part of Google and SRP’s effort to advance new non-lithium-ion long-duration energy storage technologies Energy Dome, a leading provider of innovative capacity solutions for utilities and AI infrastructure, and Salt River Project (SRP), a not-for-profit public power utility serving the greater Phoenix metropolitan area, today announced an agreement to add a 19 megawatt (MW), 10-hour carbon dioxide-based (CO2) battery system to the grid. The project is planned to be co-located on the site of SRP’s Coronado Generating Station (CGS) in St. Johns, Arizona, and it will be developed under a 20-year tolling agreement, with Energy Dome owning and operating the facility and SRP dispatching its output. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260615027901/en/ Image: Rendering of Energy Dome’s energy storage system located at the Coronado Generating Station site The project is also part of Google and SRP’s innov
SLB Launches Digital Marketplace to Scale AI and Digital Innovation Across Energy15.6.2026 14:15:00 CEST | Press release
Curated marketplace connects energy professionals, developers and partners to discover, deploy and scale trusted AI agents, domain models and digital applications Global energy technology company SLB (NYSE: SLB) today announced the launch of the SLB Digital Marketplace, a curated digital destination designed to help energy companies rapidly discover and deploy specialized AI agents, domain models, skills, tools, data connectors and digital applications within their existing digital environments. The SLB Digital Marketplace extends the company’s open platform strategy to its Tela™ agentic AI assistant by enabling SLB, partners, independent software vendors (ISVs), developers and customers to bring purpose-built digital capabilities to the energy industry through a single, governed channel. All marketplace offerings are certified against SLB standards for security, interoperability and compatibility before listing. The launch comes as the industry moves toward agentic AI — where software
Thales at Eurosatory 2026: Ready today. Ready tomorrow15.6.2026 14:01:00 CEST | Press release
Thales pavilion (stand C247),Parc des Expositions, Paris Nord Villepinte, FranceMonday 15 to Friday 19 June, 2026. As Eurosatory 2026 opens its doors, Thales is pleased to share with you a complete overview of the announcements that will be made during the first day of this international defense and security show. This document centralises all our news, innovations and partnerships, released on June, 15th, 2026 with direct links to the associated press releases: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260615204020/en/ Thales at Eurosatory 2026: Ready today. Ready tomorrow.Thales unveils new AI-powered training data analytics platform to enhance military training.Thales launches next-generation 70mm laser-guided rocket dedicated for counter-drone operations.Thales unveils next-generation Bushmaster Mulga Utility Variant.Thales launches RapidStriker, a complete system for protection against drones.Renault Group and Thal
Biocytogen Earns Full AAALAC Accreditation, Reinforcing Excellence in Translational Research and Drug Discovery15.6.2026 14:00:00 CEST | Press release
Biocytogen today announced that its Boston research facility has been awarded Full Accreditation by AAALAC International, a globally recognized organization dedicated to promoting excellence in laboratory animal care and use. The accreditation reflects Biocytogen’s continued commitment to maintaining the highest standards of animal welfare, scientific integrity, and operational excellence across its preclinical research and drug discovery activities. Biocytogen’s Boston facility serves as a key hub supporting the company’s expanding portfolio of drug discovery and translational research capabilities. The facility enables a broad range of in vivo studies supporting antibody therapeutics, multispecific antibodies, ADCs, cell therapies, and other innovative biologics programs for pharmaceutical and biotechnology partners worldwide. Through its proprietary BioMice™ platform, Biocytogen has established one of the industry’s most comprehensive collections of genetically engineered disease mo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom